This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Barrios, V. Articles by Navarro-Cid, J. PubMed PubMed Citation Articles by Barrios, V. Articles by Navarro-Cid, J. Social Bookmarking                         What's this?

Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study

Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain, vbarriosa{at}meditex.es

Carlos Escobar

Department of Cardiology, Hospital Infanta Sofia, Madrid, Spain

Alberto Calderón

Primary Health Care Centre Rosa de Luxemburgo, Madrid, Spain

Rocio Echarri

Department of Nephrology, Hospital Infanta Sofia, Madrid, Spain

Sara Barrios

Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain

Josefa Navarro-Cid

Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain

Introduction. This study examined the influence of diabetes on left ventricular hypertrophy (LVH) detected by different electrocardiographic (ECG) criteria and its changes induced by a 12-month candesartan-based regimen.

Methods. The patients were treated for a 12-month period with a candesartan-based regimen (8/16 mg + hydrochlorothiazide12.5 mg + additional drugs to target blood pressure < 140/90 mmHg [< 130/80 in diabetics]). Cornell voltage index (CorV), Cornell product (CorP), Sokolow-Lyon voltage index (SokV), and Sokolow-Lyon product (SokP) were calculated. In total 276 patients were included, 51 with diabetes.

Results. At study end, blood pressure was reduced 19.0±9.2/7.3±3.4 mmHg in diabetic patients and 18.8±9.1/8.0±3.2 mmHg in non-diabetic subjects (both p<0.01 vs. baseline; p=0.85 between groups).At baseline, 37.5% of diabetic and 26.4% of non-diabetic patients fulfilled criteria of ECG-LVH by CorP (p=0.02), 25.7% and 23.2%, respectively, by SokP (p=0.18), 11.8% and 13.7% by CorV (p=0.16), and 14.3% and 11.6% by SokV (p=0.10).At study end, the prevalence of ECG-LVH was reduced to 25.1% (relative risk reduction [RRR] 33.3%, p=0.001) and 18.2% (RRR 29.2%, p=0.001) by CorP and SokP, in diabetic patients, respectively. In non-diabetic patients, only the CorP criterion showed a significant decrease (RRR 18.9%, p=0.01). No significant changes were observed by other criteria.The RRR of ECG-LVH with treatment was significantly higher in diabetics according to CorP and SokP criteria.

Conclusions. The prevalence of ECG-LVH detected by CorP was higher in diabetics. Diabetics achieved higher reductions in ECG-LVH prevalence than non-diabetics with a candesartan-based regimen.

Key Words: candesartan • diabetes • electrocardiogram • left ventricular hypertrophy • regression

References

• Bell DS Hypertension and diabetes: a toxic combination. Endocr Pract 2008;14:1031-9.[Medline] [Order article via Infotrieve]
• Umpierrez GE, Smiley D., Robalino G. et al. Intravenous intralipid-induced blood pressure elevation and endothelial dysfunction in obese African-Americans with type 2 diabetes. J Clin Endocrinol Metab 2009;94:609-14.[Abstract/Free Full Text]
• Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006;49:1761-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Barrios V., Escobar C., Calderon A., Ribas L., Marti D., Asin E. Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population. Blood Press 2008;17:110-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Palmieri V., Bella JN, Arnett DK et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation 2001;103:102-07.[Abstract/Free Full Text]
• Dawson A., Morris AD, Struthers AD The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 2005;48:1971-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Struthers AD, Morris AD Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 2002;359:1430-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lindholm LH, Ibsen H., Dahlöf B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Levy D., Salomon M., D’Agostino RB, Belanger AJ, Kannel WB Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93.[Abstract/Free Full Text]
• Bella JN, Devereux RB Is echocardiography essential in the management of newly diagnosed hypertension? Am J Hypertens 2006;19:1156-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.[Abstract/Free Full Text]
• Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Okin PM, Devereux RB, Jern SS et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9.[Abstract/Free Full Text]
• Isobe N., Taniguchi K., Oshima S. et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J 2002;66:993-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Barrios V., Calderon A., Escobar C. et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice. The SARA study. J Hypertens 2007;25:1967-73.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Escobar C., Barrios V., Calderón A. et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA study. J Clin Hypertens 2008;10:208-14.[CrossRef][Web of Science]
• Casale PN, Devereux RB, Kligfield P. et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol 1985;6:572-80.[Abstract]
• Okin PM, Roman MJ, Devereux RB, Pickering TG, Borer JS, Kligfield P. Time-voltage area of the 12-lead electrocardiogram. Detection of left ventricular hypertrophy. Hypertension 1998;31:937-42.[Abstract/Free Full Text]
• Okin PM, Roman MJ, Devereaux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995;25:417-23.[Abstract]
• Alfakih K., Walters K., Jones T., Ridgway J., Hall AS, Sivananthan M. New gender-specific partition values for ECG criteria of left ventricular hypertrophy. Recalibration against cardiac MRI. Hypertension 2004;44:175-9.[Abstract/Free Full Text]
• Barrios V., Escobar C., Calderón A. et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst 2006;7:236-42.[Abstract/Free Full Text]
• Okin PM, Devereux RB, Harris KE et al. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2007;50:984-90.[Abstract/Free Full Text]
• Verdecchia P., Reboldi G., Angeli F. et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9.[Abstract/Free Full Text]
• Galderisi M., Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991;68:85-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Barrios V., Escobar C., Calderon A. et al. Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study. Heart Vessels 2009;(In press).
• Okin PM, Devereux RB, Gerdts E. et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006;113:1588-96.[Abstract/Free Full Text]
• Barrios V., Escobar C., Calderón A., Vegazo O., Fernandez R., Asín E. Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice. Diabetes Res Clin Pract 2007;77:492-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Okin PM, Devereux RB, Jern S., Kjeldsen SE, Julius S., Dählof B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension 2000;36:766-73.[Abstract/Free Full Text]

This version was published on September 1, 2009

Journal of Renin-Angiotensin-Aldosterone System, Vol. 10, No. 3, 168-173 (2009)
DOI: 10.1177/1470320309343596


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Barrios, V. Articles by Navarro-Cid, J. PubMed PubMed Citation Articles by Barrios, V. Articles by Navarro-Cid, J. Social Bookmarking                         What's this?